Clinical Trials Logo

Hemorrhage clinical trials

View clinical trials related to Hemorrhage.

Filter by:

NCT ID: NCT04959812 Active, not recruiting - Healthy Clinical Trials

Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Sufentanil

Start date: March 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will examine how sufentanil (a commonly used pain medication) will alter responses to simulated blood loss in humans. To simulate blood loss in the research laboratory, participants will complete a test with their lower body in a custom-designed vacuum chamber for a brief period of time.

NCT ID: NCT04959396 Recruiting - Clinical trials for Heavy Menstrual Bleeding

IUB SEAD RED (Revolutionary Endometrial Ablation Device Study

HMB
Start date: September 1, 2021
Phase: N/A
Study type: Interventional

One of the AUB symptoms, heavy menstrual bleeding (HMB), can lead to iron deficiency and iron deficiency anemia and in acute and severe cases, can necessitate emergency medical care. This study's focus is on the symptom of HMB which has a number of benign causes. The investigative device, the IUB SEADâ„¢, is a novel spherical endometrial ablation device developed to allow for simple, office-based chemical EA to treat benign causes of the symptom of HMB. The suggested procedure is expected to be simpler than the currently available EA methods and yet should still reduce the need for hysterectomy.

NCT ID: NCT04958525 Recruiting - Clinical trials for Basal Ganglia Hemorrhage

Minimally Invasive Treatment of Hypertensive Basal Ganglia Hemorrhage by Transfrontal Keyhole Neuroendoscopy

Start date: February 1, 2021
Phase:
Study type: Observational

To compare the prognosis of patients with hypertensive intracerebral hemorrhage treated by two different surgical methods, and to clarify the therapeutic effect of minimally invasive surgery, so as to find a better surgical method that can reduce surgical trauma and mortality and improve the prognosis of patients

NCT ID: NCT04957862 Not yet recruiting - Clinical trials for Hypertensive Intracerebral Hemorrhage

Robotic Assisted Evacuation of Subacute and Chronic Supratentorial Deep Hypertensive Intracerebral Hemorrhage

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

Robotic Assisted Evacuation of Subacute and Chronic Supratentorial Deep Hypertensive Intracerebral Hemorrhage for Accelerating Functional Rehabilitation (RESCUE-CHAIN): a Multi-center Randomized Controlled Trial

NCT ID: NCT04957849 Not yet recruiting - Clinical trials for Hypertensive Intracerebral Hemorrhage

Acute Hypertensive Cerebral Hemmorrhage Surgery

NET-OCEAN
Start date: January 1, 2022
Phase: N/A
Study type: Interventional

The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery: a Multi-center Clinical Trial

NCT ID: NCT04955028 Completed - Clinical trials for Cesarean Scar Pregnancy

MRI in Predicting Intraoperative Massive Hemorrhage for Cesarean Scar Pregnancy

Start date: January 27, 2015
Phase:
Study type: Observational

MRI features and clinical characteristics to predict massive hemorrhage during hysteroscopic treatment of CSP, and to aid the choice of treatment.

NCT ID: NCT04953949 Completed - Clinical trials for Oozing (Hemorrhage) During Intracranial Procedures

IEIK13 For Neurosurgery

Start date: August 6, 2021
Phase: N/A
Study type: Interventional

The objective of this clinical investigation is to determine the performance and safety profile of NU-MAX® when used as a topical hemostat for oozing bleedings encountered during intracranial procedures, in which control of bleeding by conventional hemostatic techniques is either ineffective or impractical.

NCT ID: NCT04951570 Completed - Clinical trials for Intracerebral Hemorrhage

Clinical Diagnosis and Treatment of Intracerebral Hemorrhage Based on Artificial Intelligence

CATCH-AI
Start date: June 23, 2021
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to test the reliability and validity of an artificial intelligence system and a related 5-score scale to predict hematoma expansion, and conduct a study cohort of intracerebral hemorrhage to screen out imaging and biological markers that could predict hematoma expansion in real-world.

NCT ID: NCT04951453 Active, not recruiting - Clinical trials for Traumatic Brain Injury

Systemic Nitrosative/Oxidative Stress in Patients With Acute Brain Injury

NOX
Start date: August 18, 2021
Phase:
Study type: Observational

Acute brain injury due to traumatic brain injury (TBI), intracerebral haemorrhage (ICH), and aneurysmal subarachnoid haemorrhage (SAH) carries a high morbidity and mortality, in part due to the development of secondary brain injury. The mechanisms behind secondary brain injury are incompletely understood, but oxidative/nitrosative stress and disturbances in the metabolism of the vasodilator nitric oxide (NO) are believed to be involved. The aim of the present study is to characterise systemic changes in markers of oxidative/nitrosative stress and NO metabolism in the early phase after acute brain injury, and to examine their relationship to clinical course, neurological outcome, and mortality.

NCT ID: NCT04946006 Completed - Clinical trials for Postpartum Hemorrhage

Maintenance Infusion of Oxytocin Following Elective Cesarean Deliveries

Start date: July 26, 2021
Phase: N/A
Study type: Interventional

This study is designed to determine the minimal effective oxytocin maintenance dose required during cesarean delivery to achieve the best effect. Oxytocin is a drug which is routinely used to help contract the uterus and keep it contracted after the delivery of the baby and placenta. The aim of oxytocin is to reduce the amount of blood that might be lost. In order to determine the minimal effective dose, the investigators will conduct a dose-finding study. The first patient will receive a set oxytocin infusion. If the uterus contracts well, this is considered satisfactory and the next patient will receive the same dose. If the uterus does not contract well, this is considered unsatisfactory and the next patient will receive a higher dose. The dose for the next patient will be determined based on the results of the uterine contraction of the previous patient. The investigators hypothesize that the ED90 of an oxytocin infusion rate to maintain a satisfactory uterine tone during a cesarean delivery in non-laboring women, would be lower than that found in previous studies without an initial bolus (less than 16 IU/h).